Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 6, 1997, Pages 605-608

  Ribeiro, Maria ^a,b   Ruff, Paul ^a,c   Falkson, Geoffrey ^b  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND MEDICAL SCHOOL   (South Africa)

Author keywords

Age; Prognostic factors; Prostate cancer; Serum testosterone

Indexed keywords

TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; ONSET AGE; PROGNOSIS; PROSTATE CANCER; TESTOSTERONE BLOOD LEVEL;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL MARKERS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROGNOSIS; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0030690915     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199712000-00015     Document Type: Article

References (15)

1. Sitas F, Pacella R. Cancer in South Africa. Johannesburg, South Africa: South African Institute for Medical Research, 1994.
2. Weiss MA, Mills SE. Neoplastic lesions of the prostate and seminal vesicles. In: Genitourinary Tract Pathology. New York: Raven Press, 1993:14.1-14.8.
3. Banach L, Stepien A. The most common cancers in Transkeian adults by histological diagnosis. S Afr Med J 1993;83:808.
4. Gerber GS, Chodak GW. Value of prostate cancer screening. Eur Urol 1993;24:161-5.
5. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-23.
6. Kozolwski JM, Emmis WJ, Grayhack JT. Advanced prostatic carcinoma: Early versus late endocrine therapy. Urol Clin N Am 1991;18:15-24.
7. Surya BV, Provet JA. Manifestations of advanced prostate cancer: Prognosis and treatment. J Urol 1989;142:921-8.
8. Soloway MS, Chodak G, Vogelzang NJ, et al. Zoladex versus orchidectomy in the treatment of advanced prostate cancer: A randomized trial. Urology 1991;37:46-51.
9. Falkson CI, Falkson G, Falkson HC. Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin. Ann Oncol 1991;2:303-4.
10. Oken MI, Davis TE, Creech RH, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
11. Wilson JM, Kemp IW, Stein GJ. Cancer of the prostate: Do younger men have a poorer survival rate? Br J Urol 1984;56: 391-96.
12. Wilson DW, Harper ME, Jensen HM, Ikeda RM, Richards G, Peeling WB, et al. A prognostic index for the clinical management of patients with advanced prostatic cancer: A British Prostate Study Group Investigation. Prostate 1985;7:131-41.
13. Kreis W, Ahmann FR, Lesser M, Scott M, Caplan R, Gau T, et al. Predictive initial parameters for response of Stage D prostate cancer to treatment with the Luteinizing Hormone Releasing Hormone agonist goserelin. J Clin Oncol 1990;8:870-4.
14. Ishikawa S, Soloway MS, van der Zwaag R, Todd B. Prognostic factors in survival free of progression after androgen deprivation therapy for treatment of prostate cancer. J Urol 1989;141:1139-42.
15. Mulders PFA, Dijkman GA, del Moral PF, Theeuwes GM, Debruyne FMJ. Analysis of prognostic factors in disseminated cancer. Cancer 1990;65:2758-61.